Search Within

Andrew D Zelenetz

Formats
  1. Meeting Abstract (461)
  2. Journal Article (288)
  3. Research Letter (14)
  4. Book Section (7)
  5. Guidelines (5)
  6. Conference Paper (3)
  7. Correspondence (3)
  8. Editorial (3)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (785)
  2. Department of Medicine (785)
  3. Hematologic Malignancies, Division of (785)
  4. Lymphoma (785)
  5. Survivorship Research (234)
  6. Population Sciences Research Program (189)

More Groups

People
  1. Craig Moskowitz (207)
  2. Ariela Noy (188)
  3. Paul Hamlin (187)
  4. Steven Horwitz (169)
  5. David Straus (163)
  6. Maria Palomba (143)

More People

Years
  1. 2025 (8)
  2. 2024 (31)
  3. 2023 (43)
  4. 2022 (30)
  5. 2021 (29)
  6. 2020 (32)

More Years

Publications
  1. Blood (329)
  2. Journal of Clinical Oncology (83)
  3. Journal of the National Comprehensive Cancer Network (35)
  4. British Journal of Haematology (34)
  5. Leukemia and Lymphoma (31)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (341)
  2. American Society of Clinical Oncology (85)
  3. John Wiley & Sons (41)
  4. Harborside Press (35)
  5. Elsevier Inc. (31)
  6. Oxford University Press (31)

More Publishers

Results (785)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schòˆder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax
    Meeting Abstract

    Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A prospective multicenter study of minimal residual disease assessment using a next-generation immunosequencing assay and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J. R.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Copley, D.; Grieve, C.; Jacob, A. P.; Joseph, A.; Laraque, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save